Two Sigma Advisers LP Has $3.88 Million Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)

Two Sigma Advisers LP lifted its holdings in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 58.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 293,300 shares of the biotechnology company's stock after buying an additional 107,800 shares during the period. Two Sigma Advisers LP owned about 0.96% of AnaptysBio worth $3,883,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Victory Capital Management Inc. boosted its position in AnaptysBio by 41.0% during the fourth quarter. Victory Capital Management Inc. now owns 334,450 shares of the biotechnology company's stock valued at $4,428,000 after purchasing an additional 97,200 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of AnaptysBio by 8.4% during the 4th quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company's stock valued at $24,411,000 after buying an additional 143,584 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of AnaptysBio during the 4th quarter valued at about $311,000. AlphaQuest LLC grew its stake in shares of AnaptysBio by 1,891.5% in the 4th quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company's stock valued at $59,000 after buying an additional 4,237 shares in the last quarter. Finally, XTX Topco Ltd increased its holdings in AnaptysBio by 97.2% in the fourth quarter. XTX Topco Ltd now owns 40,013 shares of the biotechnology company's stock worth $530,000 after buying an additional 19,727 shares during the last quarter.

AnaptysBio Stock Up 8.9%

AnaptysBio stock traded up $1.86 during trading hours on Thursday, hitting $22.76. The stock had a trading volume of 583,557 shares, compared to its average volume of 607,922. The company has a 50-day moving average of $19.57 and a two-hundred day moving average of $18.26. AnaptysBio, Inc. has a fifty-two week low of $12.21 and a fifty-two week high of $41.31. The company has a market cap of $668.69 million, a PE ratio of -3.74 and a beta of -0.20.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share for the quarter, topping analysts' consensus estimates of ($1.30) by $0.02. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The firm had revenue of $27.77 million for the quarter, compared to the consensus estimate of $15.27 million. As a group, analysts forecast that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio announced that its board has authorized a share buyback plan on Monday, March 24th that allows the company to repurchase $75.00 million in outstanding shares. This repurchase authorization allows the biotechnology company to buy up to 13.1% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company's leadership believes its stock is undervalued.

Analyst Ratings Changes

Several research firms have commented on ANAB. JPMorgan Chase & Co. increased their target price on shares of AnaptysBio from $36.00 to $42.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Wells Fargo & Company boosted their target price on AnaptysBio from $40.00 to $51.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. HC Wainwright reiterated a "neutral" rating and set a $22.00 price target on shares of AnaptysBio in a report on Tuesday, March 4th. Wedbush restated an "outperform" rating and issued a $40.00 price objective on shares of AnaptysBio in a research note on Thursday. Finally, Guggenheim reaffirmed a "buy" rating and set a $90.00 price objective (up from $54.00) on shares of AnaptysBio in a report on Wednesday. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $40.38.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.